Kezar Life Sciences KZR 深 滬
等待開盤 11-12 09:30:00 美东时间
7.29
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 7.29
- 總市值 5385.63万
- 52周最高 7.55
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.5334
- 委 比 0.00%
- 總股本 738.77万
- 歷史最高 363.27
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.5334
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah
Ms. Economides brings more than two decades of experience in biotech finance, corporate development and capital markets. Over her career, she has helped execute more than $1 billion in equity financings, non-dilutive financings, and other strategic transactions. She joined Adial as Executive Vice Pr...
10-26 20:04
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals announced that Celia Economides, its current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer, succeeding Vinay Shah. Economides brings over two decades of experience in biotech finance, having raised over $1 billion in financings. She will lead the Company’s finance organization as it transitions to Azora Therapeutics and advances AT177 toward the clinic. Adial plans to change its nam...
10-26 12:00
Tang Capital takes 10% stake in Aurinia Pharma
Tang Capital Management Tuesday said that it acquired 206,005 common shares of Aurinia Pharmaceuticals (AUPH) at a price of $15.28 per share for an aggregate purchase price of $3.1M. As a result of th...
06-03 15:54
Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq
An update from Kezar Life Sciences ( ($KZR) ) is now available. On May 11, 2026...
05-11 22:03
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
Kezar Life Sciences Announces Major Executive Leadership Changes
Kezar Life Sciences ( ($KZR) ) has issued an announcement. On April 1, 2026, Ke...
04-04 05:27
Aurinia Pharmaceuticals acquiring Kezar Life Sciences
Aurinia Pharmaceuticals (AUPH) is acquiring Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one contingent value right. The CVR gives the shareholder the right to re...
03-30 22:06
Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
03-30 20:04
Enodia Therapeutics Acquires Kezar Life Sciences Preclinical Assets For Up to $127M Plus Royalties
Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory
03-12 21:06
